

Laboratory di cosmetics indu	_	raw	materials	for	the	pharmaceutical	and
TECHNICAL DATA SHEET			www.guinama.com Telf.: (+34) 96 186 90 90 tecnica@guinama.com				
Review date: 0	9.12.2022				ion: 4		

GUINAMA PLO GEL

Base for Compounding

1. General						
Information	Name: GUINAMA PLO GEL Bulk code: 10315					
2. Description	Transdermal gel cream ready for use as an alternative to traditionally made PLO gels. Contains Transcutol P® and Pluronic® that enhance penetration and increase absorption of the active ingredient, emollients to improve its feel and spreadability, and emulsifiers that prevent the PLO from thinning at low temperatures. The active ingredients can be added directly, or sprayed or dispersed in a suitable solvent. Can be used in analgesics (to include pain relief substances), sports medicine and veterinary medicine.					
3. Composition	AQUA, POLOXAMER 407, ETHOXYDIGLYCOL, ISOPROPYL PALMITATE, LECITHIN, ARGILLA, HYDROXYETHYL ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE COPOLYMER, PHENOXYETHANOL, POLYGLYCERYL-3 DIISOSTEARATE, SQUALANE, GLYCERYL STEARATE, PEG-100 STEARATE, POLYSORBATE 60, ETHYLHEXYLGLYCERIN, SORBITAN ISOSTEARATE					
4. Physicochemical Characteristics	Physical characteristics	Transdermal O/W Gel Cream				
	рН	5.0 - 8.0				
	pH range	3.0 - 11.0				
	Density	0.9 - 1.1 g/ml				
	Viscosity	250,000 - 300,000 cps				
	Penetration capability	Very good				
	Load capacity (hydro - lipo)	Hydrophilic 10% - Lipophilic 20%				
	Can be replaced with/	PLO gels				
5. Properties/Uses	 Compounding base. Can include acidic and alkaline active ingredients without breaking. More cosmetic and more spreadable finish than a usual PLO gel. Compatible with lipophilic and hydrophilic APIs. Can incorporate ionic and non-ionic active ingredients. 					

	 Active ingredients can be added directly to the Guinama PLO Gel. If desired, active ingredients can be pre-dispersed in water, glycerin, PEG, alcohol or isopropyl palmitate to form a solution/paste before adding them to the Guinama PLO Gel. Stable at low temperatures. Contains skin penetration enhancers. Base prepared for use; moisturising agents not required. Given its composition, the drug is more efficiently absorbed. Thanks to transdermal administration of active ingredients in veterinary medicine, treatment compliance is increased, especially in felines. Reduction in the first-pass hepatic effect, reducing adverse reactions to certain medicines. Rotating the area of application for the mix is recommended. Allows the concentration of the active ingredient to be increased in the place of pain to be treated in palliative treatments for pain. Has undergone stability tests. 			
6. Recommended packaging	SAMIX SINGLE-DOSE packaging, aluminium tube with dispensing syringe, and pump dispensers, like airless packaging ones that control the dose dispensed in each application.			
7. Toxicity or precautions for use	For topical external use. Do not apply to wounds or the mucosa. Do not swallow. For more detailed information, see the safety data sheet.			
8. Storage	Store at room temperature (25±2°C) in a cool, dry place away from sunlight, in a tightly closed container.			
9.Incompatibilities	Compatible with moderate levels of active pharmaceutical ingredients.			
10. Bibliography	 Compounding Today. Formula 826 Manual del paliativista. Jose Luis Rodriguez Dominguez. Page 40. 			